AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29191135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 360
Study 29191135 — intervention group
Group type: COMPARATOR
Intervention: Neutral message
Number of subjects: 360
Study 29191135 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 360
Study 29169314 — intervention group
Group type: EXPERIMENTAL
Intervention: Wideband amplification
Number of subjects: 73
Study 29169314 — intervention group
Group type: COMPARATOR
Intervention: Digital Noise Reduction (DNR)
Number of subjects: 73
Study 29169314 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing
Number of subjects: 73
Study 29169314 — intervention group
Group type: COMPARATOR
Intervention: DNR
Number of subjects: 73
Study 26156737 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg vitamin D₃/d
Number of subjects: 226
Study 26156737 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D₃/d
Number of subjects: 226
Study 26156737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D₃/d
Number of subjects: 226
Study 23816038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone intervention providing monthly self-management support and quarterly medication management facilitation
Number of subjects: 359
Study 23816038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 359
Study 20103547 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 815
Study 20103547 — intervention group
Group type: COMPARATOR
Intervention: Individual care (Control)
Number of subjects: 815
Study 18431475 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Doctor counseling
Number of subjects: 476
Study 16385521 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab + MTX
Number of subjects: 24
Study 16385521 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 24
Study 12741142 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic antioxidant system activity in larynx cancer patients
Number of subjects: 28
Study 10779419 — intervention group
Group type: EXPERIMENTAL
Intervention: BFM treatment with cranial irradiation
Number of subjects: 5006
Study 10779419 — intervention group
Group type: COMPARATOR
Intervention: BFM treatment without cranial irradiation
Number of subjects: 5006
Study 8865468 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 23
Study 8865468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1738794 — intervention group
Group type: COMPARATOR
Intervention: Deprivation plus no nicotine gum (n = 10)
Number of subjects: 60
Study 1738794 — intervention group
Group type: COMPARATOR
Intervention: Deprivation plus 0 mg nicotine gum (n = 20)
Number of subjects: 60
Study 1738794 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation plus 2 mg nicotine gum (n = 20)
Number of subjects: 60
Study 1738794 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation plus 4 mg nicotine gum (n = 20)
Number of subjects: 60
Study 6627992 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar gel (psoriGel) treatment for five days, followed by vegetable oil soaking on the sixth day and no treatment on the seventh day.
Number of subjects: 112
Study 6627992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tar shampoo (Ionil T) after initial treatment.
Number of subjects: 112
Study 6627992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontar shampoo after initial treatment.
Number of subjects: 112
Study 31922359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid revascularization
Number of subjects: 60
Study 31922359 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 60
Study 29432913 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg per day for consecutive weeks)
Number of subjects: 0
Study 29432913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26721330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine (HD)
Number of subjects: 105
Study 26721330 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine (SD)
Number of subjects: 105
Study 24267397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional bipolar RF
Number of subjects: 20
Study 24267397 — intervention group
Group type: COMPARATOR
Intervention: Fractional erbium-doped glass
Number of subjects: 20
Study 23250592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy along with standard medications
Number of subjects: 48
Study 23250592 — intervention group
Group type: COMPARATOR
Intervention: Standard medications
Number of subjects: 48
Study 20054282 — intervention group
Group type: EXPERIMENTAL
Intervention: Full solid diet
Number of subjects: 210
Study 20054282 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet
Number of subjects: 210
Study 20054282 — intervention group
Group type: COMPARATOR
Intervention: Soft diet
Number of subjects: 210
Study 18724186 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban HIV/STD Risk Reduction Intervention
Number of subjects: 0
Study 18724186 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion Intervention (Control)
Number of subjects: 0
Study 15963199 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) via HFA-MDI
Number of subjects: 0
Study 15963199 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg/fluticasone propionate 250 microg (one puff, twice daily) via Diskus inhaler
Number of subjects: 0
Study 12621133 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin daily
Number of subjects: 1121
Study 12621133 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin daily
Number of subjects: 1121
Study 12621133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study 12110626 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug treatment (MDT)
Number of subjects: 100
Study 12110626 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 100
Study 10674680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 121
Study 10674680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 121
Study 7784531 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex finger movements
Number of subjects: 0
Study 7784531 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveally presented precue with varying intervals (0, 100, 300, or 1,400 ms)
Number of subjects: 0
Study 7784531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlateralized, response-locked negativity
Number of subjects: 0
Study 2207888 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 21
Study 2207888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7437209 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (i.m. administration)
Number of subjects: 20
Study 7437209 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (i.v. administration)
Number of subjects: 20
Study 7437209 — intervention group
Group type: COMPARATOR
Intervention: Postoperative analgesic requirement (women)
Number of subjects: 20
Study 7437209 — intervention group
Group type: COMPARATOR
Intervention: Postoperative analgesic requirement (men)
Number of subjects: 20
Study 30860682 — intervention group
Group type: EXPERIMENTAL
Intervention: LaVita® supplementation
Number of subjects: 0
Study 30860682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27825694 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (decision aid)
Number of subjects: 204
Study 27825694 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study 25855342 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 0.5 mg
Number of subjects: 40
Study 25855342 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 1 mg
Number of subjects: 40
Study 25855342 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg
Number of subjects: 40
Study 25855342 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 5 mg
Number of subjects: 40
Study 25855342 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (all doses)
Number of subjects: 40
Study 25855342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23494688 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and monitoring program for frail elderly patients based on routine care information in general practice
Number of subjects: 3008
Study 23494688 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program by trained nurses for frail elderly patients in general practice
Number of subjects: 3008
Study 23494688 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3008
Study 23494688 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and monitoring program
Number of subjects: 3008
Study 23494688 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 3008
Study 21372706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliced orange intervention (OI)
Number of subjects: 60
Study 21372706 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing (control)
Number of subjects: 60
Study 21372706 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange aromatherapy intervention (OAI)
Number of subjects: 60
Study 19665366 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated intravenous fluids (heated in a cabinet set at 45 degrees C)
Number of subjects: 75
Study 19665366 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated intravenous fluids (via Hotline fluid warmer)
Number of subjects: 75
Study 19665366 — intervention group
Group type: COMPARATOR
Intervention: Room temperature intravenous fluids
Number of subjects: 75
Study 17038409 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of contrast material (300 mg I ml(‐1)) only (Group A)
Number of subjects: 52
Study 17038409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material pushed with 50 ml of saline solution (Group B)
Number of subjects: 52
Study 17038409 — intervention group
Group type: EXPERIMENTAL
Intervention: 85 ml of contrast material pushed with 50 ml of saline solution (Group C)
Number of subjects: 52
Study 15104829 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVH type ID (laparoscopic‐assisted abdominal colpotomy)
Number of subjects: 541
Study 15104829 — intervention group
Group type: COMPARATOR
Intervention: LAVH type IA (vaginal approach to colpotomy)
Number of subjects: 541
Study 11498314 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 1 mg/kg combined with 50 microg/kg of morphine
Number of subjects: 46
Study 11498314 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 50 microg/kg
Number of subjects: 46
Study 9021940 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in group 1 (normal renal function)
Number of subjects: 17
Study 9021940 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in group 2 (renal failure)
Number of subjects: 17
Study 9021940 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in both groups
Number of subjects: 17
Study 7889965 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefuroxime (20 mg/kg intravenously at induction of anaesthesia)
Number of subjects: 844
Study 7889965 — intervention group
Group type: COMPARATOR
Intervention: Three-day course of cefuroxime (20 mg/kg intravenously at induction followed by 750 mg t.i.d. for three consecutive days)
Number of subjects: 844
Study 2851413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 7500 AXaU, subcutaneously, starting 2 hours before surgery and continuing for 7 days
Number of subjects: 100
Study 2851413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2851413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 100
Study 29504044 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen (60,000 IU weekly)
Number of subjects: 67
Study 29504044 — intervention group
Group type: COMPARATOR
Intervention: Stoss regimen (600,000 IU on day 1)
Number of subjects: 67
Study 26382252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway-managed group (n=54)
Number of subjects: 114
Study 26382252 — intervention group
Group type: COMPARATOR
Intervention: Nonpathway group (n=60)
Number of subjects: 114
Study 24360025 — intervention group
Group type: EXPERIMENTAL
Intervention: Half volume group (cuff inflated with half the maximum inflation volume)
Number of subjects: 80
Study 24360025 — intervention group
Group type: COMPARATOR
Intervention: Resting volume group (cuff inflated with resting volume)
Number of subjects: 80
Study 24360025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 22427534 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of all biomarkers (including IL-6, fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein, Clara cell secretory protein-16, IL-6 and -8, tumor necrosis factor-α)
Number of subjects: 1843
Study 22427534 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 alone
Number of subjects: 1843
Study 22427534 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables (age, BODE, hospitalization history)
Number of subjects: 1843
Study 20377320 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (75-375 mg once or twice a month by subcutaneous injection)
Number of subjects: 246
Study 20377320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 18760150 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills treatment program (12-week program with weekly 3-hour group sessions and 1-hour individual sessions)
Number of subjects: 51
Study 18760150 — intervention group
Group type: COMPARATOR
Intervention: Social activity alone
Number of subjects: 51
Study 18760150 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 51
Study 18760150 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills treatment program
Number of subjects: 51
Study 21961347 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (90%) applied once to the cervix, cul de sacs, and vagina areas
Number of subjects: 28
Study 21961347 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 28
Study 14716791 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II axillary node dissection
Number of subjects: 1209
Study 14716791 — intervention group
Group type: COMPARATOR
Intervention: Level III axillary node dissection
Number of subjects: 1209
Study 11205721 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific and individualized treatment for diastolic heart failure (DHF)
Number of subjects: 0
Study 11205721 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8737632 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg sustained release film tablets
Number of subjects: 100
Study 8737632 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg sustained release film tablets
Number of subjects: 100
Study 8737632 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg normally releasing capsules
Number of subjects: 100
Study 8737632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution (1 x 1000 mg/d)
Number of subjects: 100
Study 8737632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1410128 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg velnacrine maleate
Number of subjects: 0
Study 4073082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid
Number of subjects: 25
Study 4073082 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 25
Study 2890542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation containing standardized ginseng extract combined with trace elements and multivitamins
Number of subjects: 24
Study 2890542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28884306 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic soy milk (200 mL/day)
Number of subjects: 48
Study 28884306 — intervention group
Group type: COMPARATOR
Intervention: Soy milk (control)
Number of subjects: 48
Study 28328980 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of cerebral oxygenation by near-infrared spectroscopy with treatment guidelines
Number of subjects: 166
Study 28328980 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study 26144663 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based feedback training
Number of subjects: 24
Study 26144663 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 24
Study 22638708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention comprising regular dietetic counseling and oral nutritional supplementation for 3 months postoperatively
Number of subjects: 152
Study 22638708 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 152
Study 22638708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention
Number of subjects: 152
Study 21649534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 367
Study 21649534 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 367
Study 18270213 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM treatment for 3 months
Number of subjects: 164
Study 18270213 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 3 months
Number of subjects: 164
Study 16815148 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of prednisolone daily for 14 days
Number of subjects: 40
Study 16815148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14662044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus topotecan (Arm 1, 12 patients)
Number of subjects: 57
Study 14662044 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 230 mg/m2 plus topotecan (Arm 3, 13 patients)
Number of subjects: 57
Study 14662044 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 plus topotecan (Arm 4, 32 patients)
Number of subjects: 57
Study 10455827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1.25 micrograms.kg‐1.min‐1)
Number of subjects: 40
Study 10455827 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin (0.5 ng.kg‐1.min‐1)
Number of subjects: 40
Study 7675940 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC 756 (80 mg)
Number of subjects: 3
Study 2088189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg) intravenously every 12 h
Number of subjects: 23
Study 2088189 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g) intravenously every 8 h
Number of subjects: 23
Study 230654 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasotocin (AVT) administered subcutaneously at 22.00 and 01.00 h, doses between 2 and 12 micrograms
Number of subjects: 14
Study 230654 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasotocin (AVT) administered intravenously or perfused to 10 normal adult subjects, doses between 2 micrograms perfused for 4 hours and 12 micrograms perfused for 30 minutes
Number of subjects: 14
Study 230654 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously
Number of subjects: 14
Study 31685270 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to an online video during consent process
Number of subjects: 50
Study 31685270 — intervention group
Group type: COMPARATOR
Intervention: Conventional, face-to-face consenting without access to the online video
Number of subjects: 50
Study 29808340 — intervention group
Group type: EXPERIMENTAL
Intervention: eSNAP intervention
Number of subjects: 40
Study 29808340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 26095773 — intervention group
Group type: EXPERIMENTAL
Intervention: EarPopper(®) device
Number of subjects: 29
Study 26095773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 24036408 — intervention group
Group type: EXPERIMENTAL
Intervention: PUSH HARD
Number of subjects: 128
Study 24036408 — intervention group
Group type: COMPARATOR
Intervention: TWO INCHES
Number of subjects: 128
Study 22902795 — intervention group
Group type: EXPERIMENTAL
Intervention: Argentine tango dance program (12 months, twice-weekly classes)
Number of subjects: 52
Study 22902795 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 52
Study 20592125 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 10
Study 20592125 — intervention group
Group type: EXPERIMENTAL
Intervention: individual alpha frequency rTMS
Number of subjects: 10
Study 20592125 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Number of subjects: 10
Study 20592125 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 10
Study 20592125 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 10
Study 18414100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost applied once daily for 7 days in one-eye trials
Number of subjects: 41
Study 18414100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral treatment with latanoprost
Number of subjects: 41
Study 18414100 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of mean diurnal IOP reduction between 2 one-eye trials
Number of subjects: 41
Study 18414100 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of fellow eyes in bilateral treatment
Number of subjects: 41
Study 18414100 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of baseline IOP at each time point between fellow eyes in one-eye trials and bilateral treatment
Number of subjects: 41